The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Comparison of atezolizumab monotherapy to docetaxel with and without ramucirumab in patients with advanced non-small-cell lung cancer who received prior immunotherapy.
 
Shenduo Li
No Relationships to Disclose
 
Jyothik Varun Inampudi
No Relationships to Disclose
 
Koshiya R Hiren
No Relationships to Disclose
 
Jaydeepbhai Patel
No Relationships to Disclose
 
Rami Manochakian
Stock and Other Ownership Interests - Alpha 2
Consulting or Advisory Role - Alpha 2; AstraZeneca; Cardinal Health; Guardant Health; Janssen; Novocure; Takeda; Turning Point Therapeutics
 
Yujie Zhao
Employment - Mayo Clinic; Mayo Clinic
Honoraria - Coherus Biosciences; Lilly
Consulting or Advisory Role - Coherus Biosciences; Lilly
Research Funding - Alpine Immune Sciences (Inst); Incyte (Inst); Merck (Inst); Mirati Therapeutics (Inst); PDS Biotechnology; Pfizer (Inst); Zai Lab
 
Yanyan Lou
Consulting or Advisory Role - AstraZeneca; Janssen; Lilly; Turning Point Therapeutics
Research Funding - Blueprint Medicines (Inst); Daiichi-Sankyo (Inst); Genmab (Inst); Merck (Inst); Mirati Therapeutics (Inst); Roche/Genentech (Inst); Tolero Pharmaceuticals (Inst)